What top creators are saying about Compass Pathways plc(CMPS)
A mental health care company developing psilocybin therapy.
8 AI-extracted insights from 6 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Not enough scored insights about Compass Pathways plc in the last 30 days yet.
The Take
Sentiment for Compass Pathways plc (CMPS) is decidedly bullish across 3 sources, driven by a shifting political landscape and the anticipation of federal regulatory tailwinds for psychedelic-assisted therapies.
Bull Case
- Regulatory Tailwinds: Potential federal rescheduling of psychedelics is creating a significantly more favorable outlook for mental health biotech firms (per Joe Rogan).
- Political Momentum: Recent headlines and the possibility of executive orders regarding research are driving positive price action and investor interest (per threadguy).
- Market Sentiment: The asset is positioned as a primary beneficiary of a strong period of growth for the broader psychedelic medicine sector (per Real Vision).
Catalysts & Targets
- Potential federal rescheduling of psychedelics
- Possible executive orders regarding psychedelic research
AI-generated summary. Not investment advice. Learn more.
Top creators covering Compass Pathways plc (CMPS)
The 6 sources with the most insights about Compass Pathways plc on Kazuha.
Latest insights about Compass Pathways plc (CMPS)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Friday, May 1, 2026
Potential for federal rescheduling of psychedelics creates a favorable regulatory outlook for mental health biotech firms.
Monday, April 20, 2026
Gaining momentum due to political headlines and potential executive orders regarding psychedelic research.
Identified as a key stock benefiting from a 'great weekend' for psychedelic medicine investors.
Noted as a significant investment opportunity within the emerging psychedelic sector.
Monday, April 13, 2026
Recognized as a leader for exposure to clinical-stage developments following favorable executive action.
Thursday, March 12, 2026
Long-term bullish on therapeutic utility for PTSD and addiction, but cautious due to federal regulatory gatekeeping and political volatility during election cycles.
Monday, October 6, 2025
A major player in the psychedelic medicine field that is reportedly 'very close to approval' for its own treatment. Atai Life Sciences holds a stake in the company.
Monday, June 23, 2025
Used as a cautionary tale for biotech investors. The stock dropped 50% despite meeting its trial's primary endpoint because market expectations were higher, highlighting that positive data doesn't guarantee a positive stock reaction.
Friday, May 1, 2026
Potential for federal rescheduling of psychedelics creates a favorable regulatory outlook for mental health biotech firms.
Monday, April 20, 2026
Gaining momentum due to political headlines and potential executive orders regarding psychedelic research.
Identified as a key stock benefiting from a 'great weekend' for psychedelic medicine investors.
Noted as a significant investment opportunity within the emerging psychedelic sector.
Monday, April 13, 2026
Recognized as a leader for exposure to clinical-stage developments following favorable executive action.
Thursday, March 12, 2026
Long-term bullish on therapeutic utility for PTSD and addiction, but cautious due to federal regulatory gatekeeping and political volatility during election cycles.
Monday, October 6, 2025
A major player in the psychedelic medicine field that is reportedly 'very close to approval' for its own treatment. Atai Life Sciences holds a stake in the company.
Monday, June 23, 2025
Used as a cautionary tale for biotech investors. The stock dropped 50% despite meeting its trial's primary endpoint because market expectations were higher, highlighting that positive data doesn't guarantee a positive stock reaction.
Discussed alongside Compass Pathways plc (CMPS)
Other assets that creators frequently mention in the same content as Compass Pathways plc.
Frequently asked
Which podcasters and creators cover Compass Pathways plc (CMPS) the most?
The most active sources covering Compass Pathways plc (CMPS) on Kazuha are Real Vision Podcast Network, Joe Rogan, Blockworks, @realmartinshkreli, @notthreadguy. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Compass Pathways plc (CMPS) are on Kazuha?
Kazuha has indexed 8 AI-extracted insights about Compass Pathways plc (CMPS) from 6 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Compass Pathways plc (CMPS)?
Creators covering Compass Pathways plc (CMPS) most frequently also discuss ATAI, BTC, CYBN, BRENT, SQSP. See the "Discussed alongside" section above for full asset pages.